Skip to content

The efficacy of adding of anterior femoral cutaneous nerve block to proximal adductor canal block for patients undergoing total knee arthroplasty

The comparison of efficacy between the anterior femoral cutaneous nerve block with pooximal adductor canal block versus proximal adductor canal block alone for patients undergoing total knee arthroplasty: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20191209004
Enrollment
80
Registered
2019-12-09
Start date
2019-12-10
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OA Knee going on total knee arthroplasty - Anterior femoral cutaneous nerve block - injection into the interspace between the popliteal artery and posterior capsule of the knee (iPACK) block - Ultrasound-guided - Local infiltration analge

Interventions

AFCNB+ ACB with iPACK block is perform by 0.25% levobupivacaine 60 ml&#44
epinephrine 0.3 mg and ketorolac 30 mg Continuous ACB under ultrasound guidance is performed by injecting 0.25% levobupivacaine 20 ml and followed by 0.15% levobupivacaine 5 ml/hr for 60 hours ,ACB wi
epinephrine 0.3 mg and ketorolac 30 mg Continuous ACB under ultrasound guidance is performed by injecting 0.25% levobupivacaine 20 ml and followed by 0.15% levobupivacaine 5 ml/hr for 60 hours
Experimental Procedure/Surgery,Experimental Procedure/Surgery
Anterior femoral cutaneous nerve block plus proximal ACB block (AFCNB+ FTB),Proximal adductor canal block

Sponsors

none
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patient who was scheduled for total knee arthroplasty at King Chulalongkorn Memorial Hospital ASA class 1 to 3 ASA class 1 A normal healthy patient ASA class 2 A patient with mild systemic disease Mild diseases only without substantive functional limitations ASA class 3 A patient with severe systemic disease but not threaten to life Body mass index BMI between 18 to 40 kg m2

Exclusion criteria

Exclusion criteria: refuse to participate this study unable to cooperate or cognitive impairment eg dementia allergy to any drug in this study contraindication to neuraxial anesthesia eg coagulopathy received intraoperative periarticular injection contraindication to NSAIDs Ketorolac and Celebrex in this study chronic opioids use or diagnosed of neuropathic pain unable to performed Time up and go test

Design outcomes

Primary

MeasureTime frame
incidence of pain score 4 or over 12 hours Numerical pain rating scale

Secondary

MeasureTime frame
postoperative pain score at rest 0, 4, 8,12, 24, 36, 48 hours, 5 day and 1,2,4 week Numerical pain rating scale,postoperative pain score on movement 0, 4, 8, 24, 36, 48 hours, 5 day and 1,2,4 week Numerical pain rating scale,postoperative opioids consumption 12, 24, 48 hours Milligram of Morphine Consumption,Degree of knee flexion and extension Postoperative 0, 1, 2 Days Degree of range of motion,Timed up and go test Postoperative 1, 2 days Rehabilitation after surgery,Postoperative Complication Postoperative 0, 1, 2 Days Postoperative Nausea Vomiting, Dizziness, Fall, Sleep disturbance,Length of stay Postoperative to discharge out of hospital hours,Patient satisfaction Postoperative day 2 Satisfactory score (1-10)

Countries

Thailand

Contacts

Public ContactWirinaree Kampitak

Chulalongkorn university

nutong127@yahoo.com66899955666

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026